Stock Scorer

Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals Inc. reported revenue of 5.9M USD for the quarter ending 30 June 2026, down 53.8% from 12.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 5.9M -53.8%
Gross Profit Q1 '25 · ending 31 March 2025 2.7M -12.4%
Operating Income Q2 '26 · ending 30 June 2026 -13.1M -967.4%
Net Income Q2 '26 · ending 30 June 2026 -13.2M -6547.5%
Cost of Revenue Q1 '25 · ending 31 March 2025 700K +0.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -9.3M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -4.6M —
Shares Outstanding Q2 '26 · ending 30 June 2026 21.3M +124.6%
EPS Q2 '26 · ending 30 June 2026 -1.75 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 35.6M-12.2M-17.9M-17.6M
20242024-12-31 7.6M-65.9M-76.6M-61M
20232023-12-31 5.1M-65.8M-67M-38.9M
20222022-12-31 9M-21.3M-24.5M-19M
20212021-12-31 12M-30.9M-35.1M-28.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-305.9M
Q1 '262026-03-315M
Q4 '252025-12-315.1M
Q3 '252025-09-3014.3M
Q2 '252025-06-3012.7M
Q1 '252025-03-313.4M
Q4 '242024-12-31344K
Q3 '242024-09-30-1.8M
Q2 '242024-06-305.2M
Q1 '242024-03-313.8M
Q4 '232023-12-312M
Q3 '232023-09-302.9M
Q2 '232023-06-30182K
Q1 '232023-03-3137K
Q4 '222022-12-3168K
Q3 '222022-09-308.3M
Q2 '222022-06-30214K
Q1 '222022-03-31431K
Q4 '212021-12-310
Q3 '212021-09-300

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q1 '252025-03-312.7M
Q4 '242024-12-31-456K
Q3 '242024-09-30-2.2M
Q2 '242024-06-304.5M
Q1 '242024-03-313.1M
Q4 '232023-12-311.8M
Q3 '232023-09-302.6M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-13.1M
Q1 '262026-03-31-9.7M
Q4 '252025-12-31-7.2M
Q3 '252025-09-301.6M
Q2 '252025-06-301.5M
Q1 '252025-03-31-8.1M
Q4 '242024-12-31-11.4M
Q3 '242024-09-30-20.7M
Q2 '242024-06-30-15.2M
Q1 '242024-03-31-18.6M
Q4 '232023-12-31-23.1M
Q3 '232023-09-30-23.9M
Q2 '232023-06-30-11.6M
Q1 '232023-03-31-7.1M
Q4 '222022-12-31-6.2M
Q3 '222022-09-301.4M
Q2 '222022-06-30-9.1M
Q1 '222022-03-31-7.4M
Q4 '212021-12-31-8.5M
Q3 '212021-09-30-11.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-13.2M
Q1 '262026-03-31-9.7M
Q4 '252025-12-31-8.1M
Q3 '252025-09-30-274K
Q2 '252025-06-30204K
Q1 '252025-03-31-9.7M
Q4 '242024-12-31-16.2M
Q3 '242024-09-30-22.9M
Q2 '242024-06-30-17.2M
Q1 '242024-03-31-20.3M
Q4 '232023-12-31-24.6M
Q3 '232023-09-30-24.8M
Q2 '232023-06-30-11M
Q1 '232023-03-31-6.6M
Q4 '222022-12-31-5.9M
Q3 '222022-09-3083K
Q2 '222022-06-30-10.2M
Q1 '222022-03-31-8.5M
Q4 '212021-12-31-9.5M
Q3 '212021-09-30-12.8M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q1 '252025-03-31700K
Q4 '242024-12-31800K
Q3 '242024-09-30400K
Q2 '242024-06-30700K
Q1 '242024-03-31700K
Q4 '232023-12-31200K
Q3 '232023-09-30300K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-9.3M
Q1 '262026-03-31-9.2M
Q4 '252025-12-31-4.6M
Q3 '252025-09-309.7M
Q2 '252025-06-30-10M
Q1 '252025-03-31-12.7M
Q4 '242024-12-31-16.1M
Q3 '242024-09-30-8.6M
Q2 '242024-06-30-16.4M
Q1 '242024-03-31-19.9M
Q4 '232023-12-31-14.5M
Q3 '232023-09-30-14.8M
Q2 '232023-06-30-4.7M
Q1 '232023-03-31-4.6M
Q4 '222022-12-31-5M
Q3 '222022-09-301.8M
Q2 '222022-06-30-7.2M
Q1 '222022-03-31-8.3M
Q4 '212021-12-31-8.7M
Q3 '212021-09-30-10.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-4.6M
Q3 '252025-09-309.7M
Q4 '242024-12-31-16.1M
Q3 '242024-09-30-8.6M
Q2 '242024-06-30-16.4M
Q1 '242024-03-31-19.9M
Q4 '232023-12-31-14.7M
Q3 '232023-09-30-14.9M
Q2 '232023-06-30-4.7M
Q1 '232023-03-31-4.6M
Q4 '222022-12-31-5M
Q3 '222022-09-301.7M
Q2 '222022-06-30-7.3M
Q1 '222022-03-31-8.3M
Q4 '212021-12-31-8.9M
Q3 '212021-09-30-10.6M
Q2 '212021-06-302.2M
Q1 '212021-03-31-11.1M
Q4 '202020-12-31-6.6M
Q3 '202020-09-30-7.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3021.3M
Q1 '262026-03-3121.3M
Q3 '252025-09-309.5M
Q2 '252025-06-309.5M
Q1 '252025-03-319.5M
Q3 '242024-09-304.7M
Q2 '242024-06-304.7M
Q1 '242024-03-3146.5M
Q3 '232023-09-3046.1M
Q2 '232023-06-3045.9M
Q1 '232023-03-3143M
Q3 '222022-09-3040.3M
Q2 '222022-06-3027.5M
Q1 '222022-03-3127.5M
Q3 '212021-09-3027.5M
Q2 '212021-06-3027.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.75
Q1 '262026-03-31-1.11
Q4 '252025-12-31-1.69
Q3 '252025-09-30-2.86
Q2 '252025-06-30-7.71
Q1 '252025-03-31-11.43
Q4 '242024-12-31-10.84
Q3 '242024-09-30-9.56
Q2 '242024-06-30-5.22
Q1 '242024-03-31-1.76
Q4 '232023-12-31-1.47
Q3 '232023-09-30-1.07
Q2 '232023-06-30-0.53
Q1 '232023-03-31-0.66
Q4 '222022-12-31-0.82
Q3 '222022-09-30-1.03
Q2 '222022-06-30-1.50
Q1 '222022-03-31-1.56
Q4 '212021-12-31-1.29
Q3 '212021-09-30-1.46